Gastrointestinal involvement and manifestations in systemic mastocytosis

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1247-1253

  Sokol, Harry ^a   Georgin Lavialle, Sophie ^b   Grandpeix Guyodo, Catherine ^b   Canioni, Danielle ^b   Barete, Stéphane ^b   Dubreuil, Patrice ^c   Lortholary, Olivier ^b   Beaugerie, Laurent ^a   Hermine, Olivier ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

c Kit; Digestive tract; Histamine; Systemic mastocytosis; Tryptase

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR; BUDESONIDE; CLADRIBINE; CROMOGLYCATE DISODIUM; FIBRINOGEN; GLUCOCORTICOID; INTERFERON; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROTAMINE; PROTON PUMP INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; BONE MARROW TOXICITY; CELL INFILTRATION; CLINICAL FEATURE; DIARRHEA; DISEASE CLASSIFICATION; GASTROINTESTINAL DISEASE; HUMAN; MAST CELL; MEDIATOR RELEASE; MENTAL DISEASE; NAUSEA; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMIC MASTOCYTOSIS; VOMITING;

GASTROINTESTINAL DISEASES; HUMANS; MASTOCYTOSIS, SYSTEMIC; PROGNOSIS;

EID: 77953690788     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21218     Document Type: Review

References (58)

1. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. J Invest Dermatol. 2009 [Epub ahead of print].
2. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345-368.
3. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-453.
4. Hermine O, Lortholary O, Leventhal PS, et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One. 2008;3:e2266.
5. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727-5736.
6. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769-3772.
7. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-625.
8. Demis DJ. The mastocytosis syndrome: clinical and biological studies. Ann Intern Med. 1963;59:194-206.
9. Demis DJ, Walton MD, Higdon RS. Histaminuria in urticaria pigmentosa. A clinical study and review of recent literature with definition of the mastocytosis syndrome. Arch Dermatol. 1961;83:127-138.
10. Granerus G, Olafsson JH, Roupe G. Studies on histamine-metabolism in mastocytosis. J Investig Dermatol. 1983;80:410-416.
11. Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract. 1985;179:439-461. (Pubitemid 15103249)
12. Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis - a prospective-study. Gastroenterology. 1988;95:657-667.
13. Horan RF, Austen KF. Systemic mastocytosis - retrospective review of decades of clinical experience at the Brigham and Women's Hospital. J Investig Dermatol. 1991;96:S5-S14.
14. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
15. Kirsch R, Geboes K, Shepherd NA, et al. Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases. Mod Pathol. 2008;21:1508-1516.
16. Tebbe B, Stavropoulos PG, Krasagakis K, et al. Cutaneous mastocytosis in adults - evaluation of 14 patients with respect to systemic disease manifestations. Dermatology. 1998;197:101-108. (Pubitemid 28395833)
17. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
18. Mutter RD, Tannenbaum M, Ultmann JE. Systemic mast cell disease. Ann Intern Med. 1963;59:887-906.
19. Brunning RD, McKenna RW, Rosai J, et al. Systemic mastocytosis - extracutaneous manifestations. Am J Surg Pathol. 1983;7: 425-438.
20. Huang TY, Yam LT, Li CY. Radiological features of systemic mastcell disease. Br J Radiol. 1987;60:765-770.
21. Lorcerie B, Arveux I, Chauffert B, et al. Aspirin and systemic mastocytosis. Lancet. 1989;2:1155-1155.
22. Wienbeck M, Rohner HG, Rodermund OE, et al. [Esophageal function in mastocytosis.] Verh Dtsch Ges Inn Med. 1978;977-979.
23. Ammann RW, Vetter D, Deyhle P, et al. Gastrointestinal involvement in systemic mastocytosis. Gut. 1976;17:107-112.
24. Friedman BS, Steinberg SC, Meggs WJ, et al. Analysis of plasma histamine levels in patients with mast-cell disorders. Am J Med. 1989;87: 649-654.
25. Jarnum S, Zachariae H. Mastocytosis (urticaria pigmentosa) of skin, stomach, and gut with malabsorption. Gut. 1967;8:64-68.
26. Borda F, Uribarrena R, Riveropuente A. Gastroscopic findings in systemic mastocytosis. Endoscopy. 1983;15:342-343.
27. Clemett AR, Fishbone G, Levine RJ, et al. Gastrointestinal lesions in mastocytosis. Am J Roentgenol Radium Ther Nucl Med. 1968;103: 405-412.
28. Scolapio JS, Wolfe J, Malavet P, et al. Endoscopic findings in systemic mastocytosis. Gastrointest Endosc. 1996;44:608-610.
29. Friedman BS, Metcalfe DD. Effects of tixocortol pivalate on gastrointestinal disease in systemic mastocytosis - a preliminary study. Clin Exp Allergy. 1991;21:183-188.
30. Miner PB, Jr. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol. 1991;96:40S-43S; discussion 43S-44S.
31. Barriere H, Dreno B, Pecquet C, et al. [Systemic mastocytosis and intestinal malabsorption.] Sem Hop. 1983;59:2925-2931.
32. Braverman DZ, Dollberg L, Shiner M. Clinical, histological, and electron- microscopic study of mast-cell disease of the small bowel. Am J Gastroenterol. 1985;80:30-37. (Pubitemid 15152913)
33. Bredfeldt JE, Olaughlin JC, Durham JB, et al. Malabsorption and gastric hyperacidity in systemic mastocytosis - results of cimetidine therapy. Am J Gastroenterol. 1980;74:133-137.
34. Dantzig PI. Tetany, malabsorption, and mastocytosis. Arch Int Med. 1975;135:1514-1518.
35. Fishman RS, Fleming CR, Li CY. Systemic mastocytosis - with review of gastrointestinal manifestations. Mayo Clin Proc. 1979;54: 51-54.
36. Scott BB, Hardy GJ, Losowsky MS. Involvement of small-intestine in systemic mast-cell disease. Gut. 1975;16:918-924.
37. Bank S, Marks IN. Malabsorption in systemic mast cell disease. Gastroenterology. 1963;45:535-549.
38. Broitman SA, McCray RS, May JC, et al. Mastocytosis and intestinal malabsorption. Am J Med. 1970;48:382-389.
39. Belcon MC, Collins SM, Castelli MF, et al. Gastrointestinal hemorrhage in mastocytosis. Can Med Assoc J. 1980;122:311-314.
40. Reisberg IR, Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol. 1987;82:54-60. (Pubitemid 17231685)
41. Johnson AC, Johnson S, Lester PD, et al. Systemic mastocytosis and mastocytosis-like syndrome - radiologic features of gastrointestinal manifestations. South Med J. 1988;81:729-733.
42. Berlin C. Urticaria pigmentosa as a systemic disease. AMA Arch Dermatol. 1955;71:703-712.
43. Mickys U, Barakauskiene A, De Wolf-Peeters C, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Digest Liver Dis. 2007;39:693-697.
44. Takasaki Y, Tsukasaki K, Jubashi T, et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. Intern Med. 1998;37:484-488.
45. Awad JA, Morrow JD, Roberts LJ 2nd. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol. 1994;93:817-824.
46. Poynard T, Nataf C, Messing B, et al. Secretory diarrhea and prostaglandin D2 overproduction in systemic mastocytosis. N Engl J Med. 1982;307:186.
47. Roberts LJ 2nd, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. 1980;303:1400-1404.
48. Hirschowitz BI, Groarke JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med. 1979;90:769-771.
49. Achord JL, Langford H. The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis. Am J Med. 1980;69:610-614.
50. Feldman EJ, Isenberg JI. Effects of metiamide on gastric-acid hypersecretion, steatorrhea and bone-marrow function in a patient with systemic mastocytosis. N Engl J Med. 1976;295:1178-1179.
51. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
52. Georgin-Lavialle S, Barete S, Suarez F, et al. [Current concepts and treatment advances in systemic mastocytosis.] Rev Med Interne. 2009; 30:25-34.
53. Marrache F, Memain N, Bonte I, et al. [Treatment of systemic mastocytosis.] Rev Med Interne. 2003;24:594-601.
54. Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677-690.
55. Johansson C, Roupe G, Lindstedt G, et al. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996;25: 1-7.
56. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635-641.
57. Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938. (Pubitemid 12184094)
58. Lortholary L, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: a french multicenter study of 33 patients. Blood. 2004;104:A661.